Incidence rates of HCC were calculated by era and compared using incident rate ratios (IRRs). The association between HCC and listing era was evaluated using Cox regression and competing risk analyses, the latter considering death and LT as competing events. Of the 48,158 eligible wait-list registrants, 3112 (6.5%) received HCC exceptions after a median of 493 days. In 20,039 individuals with HCV, the incidence of HCC was 49% higher in era 3 versus era 1 (IRR 1.49, 95% confidence interval [CI] 1.24-1.79). In multivariate analysis, those in era 3 had a higher hazard of HCC compared with era 1 (hazard ratio 1.22, 95% CI 1.01-1.48). However, in multivariable competing risks analysis, with death and LT considered as competing events for de novo HCC, era was no longer associated with HCC (subdistribution hazard ratio 0.83, 95% CI 0.69-1.00).
C hronic hepatitis C virus (HCV) infection has been the leading indication for liver transplantation (LT) in the United States. (1, 2) In late 2013, the approval of sofosbuvir, a potent and safe direct-acting antiviral (DAA), heralded a revolutionary era in the treatment of chronic HCV, and there are now multiple effective DAA-based regimens available for the treatment of HCV. The efficacy and safety of DAA regimens in patients with decompensated cirrhosis have been demonstrated, with many patients exhibiting improvement in Model for EndStage Liver Disease (MELD) scores and symptoms of decompensation after sustained virologic response (SVR). (3) (4) (5) (6) Reduced rates of transplant listing and LT have been observed among patients with HCV, and patients with HCV listed for LT have demonstrated the
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potential to be removed from the LT wait-list after viral eradication. (7) (8) (9) (10) Therefore, there has been widespread optimism that the advent of DAAs for the treatment of HCV would also lead to a decrease in the burden of HCV-related hepatocellular carcinoma (HCC). (11, 12) Several recent observational studies have described an incidence and recurrence of HCC in DAA-treated patients with cirrhosis who have achieved SVR that are higher than expected. (13) (14) (15) (16) (17) This phenomenon has been postulated to be the result of a persistent disruption of immunological integrity or failure of immune surveillance, leading to a more aggressive tumor profile. (18, 19) An increased rate of HCC incidence or recurrence after DAA therapy has not been observed, however, in other cohorts of patients with cirrhosis, which largely consist of patients with compensated liver disease. (20) (21) (22) (23) (24) Overall, data to date have been conflicting, and the association between DAA therapy and HCC in patients with cirrhosis after SVR remains unclear, especially in those with more advanced disease.
In this work, we describe the incidence of HCC in a population of patients with HCV and advanced cirrhosis, using data from the U.S. transplant registry. We hypothesized that if DAA-induced SVR increases the risk of HCC meaningfully, there would be a detectable signal among patients with end-stage liver disease, who are at the highest risk. The aim of the study was to compare the incidence of HCC before and after the availability of DAA among LT candidates, while adjusting for other variables that could affect incidence.
Methods

patieNtS aNd data aCQUiSitioN
This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donor, wait-listed candidates, and transplant recipients in the US, submitted by the members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors. (25) All adult patients aged 18 years or older listed for primary LT from January 1, 2003, to December 31, 2015 , were included in the analysis, with follow-up until December 15, 2016.
Patients were included if the underlying cause of cirrhosis based on their primary listing diagnosis (by SRTR diagnostic codes or manually entered text) was HCV, hepatitis B virus (HBV), NASH, cryptogenic cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis, alpha-1 antitrypsin deficiency, hereditary hemochromatosis, or Wilson's disease. Following prior convention, patients listed with a diagnosis of cryptogenic cirrhosis with a body mass index (BMI) greater than or equal to 30 were classified as NASH. (26, 27) Patients with combined diagnoses of HCV and any other cause were classified as having liver disease due to HCV.
Patients were excluded if they lacked a unique identifier or listing diagnosis, if they had a listing diagnosis not specified in the inclusion criteria or were listed as status 1, if they had a history of prior LT, or if their follow-up time was incomplete or fewer than 180 days. To exclude prevalent cases of HCC in the cohort, all patients with a primary or secondary listing diagnosis of HCC, as well as those granted MELD exception application for HCC within 180 days of initial listing, were excluded.
Demographic and clinical data at the time of listing for LT were extracted from the SRTR database. The development of incident HCC was determined by the initial date of a MELD-HCC application, which was aRtiCle iNFoRmatioN:
prospectively entered into the SRTR database. Since 2002, patients with HCC have been eligible to receive MELD exception points and thus higher priority on the transplant list. This has been based on generally accepted histologic or imaging criteria, which were further standardized by OPTN in 2011. (28) Under the current policy, lesions are classified as HCC if there is enhancement during the late arterial phase, with features of washout during later phases, peripheral rim enhancement, or growth by 50% or more on serial imaging obtained fewer than 6 months apart. To qualify for MELD exception points, the burden of HCC must be within Milan criteria (up to three OPTN class 5A or 5B lesions, each larger than 1 cm and smaller than 3 cm, or one OPTN class 5B lesion measuring larger than 2 cm or smaller than 5 cm), prior to any locoregional therapy.
Follow-up time started 180 days after initial listing and ended at (1) the date of HCC application for those with de novo HCC, (2) December 15, 2016, for those still awaiting LT, or (3) the date of removal from the wait list for any cause, such as LT, death or clinical deterioration, or clinical improvement.
data aNalySiS
Patients were divided into three cohorts according to the time of initial registration: era 1 corresponding to the period when interferon (IFN) was the mainstay for HCV therapy (2003-2010); era 2, when protease inhibitors (PIs) were available (2011-2013); and era 3, following the introduction of sofosbuvir and other DAAs (2014 DAAs ( -2015 .
Annual HCC incidence rates (IRs) were calculated for each etiology of liver disease, and an incidence rate ratio (IRR) comparing the HCC incidence by era of LT wait listing was calculated using the Mantel-Haenszel method. Univariate and multivariate Cox proportional hazards analyses were performed to describe the association between era of LT wait listing and de novo HCC, after adjusting for risk factors known to be associated with HCC in this population. (29) The proportional hazards assumption was assessed using log-log plots and Schoenfeld residuals. Competing risks regression was performed to evaluate the association between era of LT wait listing and de novo HCC, adjusted for the same variables as previously, and with LT and death treated as competing events. The competing risks analysis considers that wait-list candidates are at risk not only for development of de novo HCC, but also for LT and death, which are considered as events rather than censored as would be in conventional survival analysis. Thus, multivariable competing risk models consider the subdistribution hazard of the cumulative incidence function (in this case, the subdistribution hazard ratio [sHR] represents the hazard of de novo HCC in the presence of these competing events).
Statistical analyses were performed using Stata (Version 12.1, College Station, TX). The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki protocol and was approved by the Queen's University Health Sciences Research Ethics Board (DMED-1688-14).
Results
Of the 147,634 wait-list registrants for LT between January 1, 2003, and December 31, 2015, in the SRTR database, 48,158 met the eligibility criteria ( Fig. 1) . Table 1 lists the characteristics of the patients included in the study. The most common etiologies Over time, the proportions of candidates with HCV and those with de novo HCC decreased, whereas those with diabetes and those with NASH, cryptogenic, and alcoholic liver disease increased.
The median duration of the observed follow-up on the LT wait-list was 493 days (interquartile range [IQR], 189-1083 days), during which 3112 (6.5%) developed de novo HCC. The incidence rate of HCC is described in Table 2 and Fig. 2 . In Table 2 , the incidence of HCC did not appear to change substantially over time in the overall registrant population: It increased modestly from 3.0 per 100 person-years (PY) in era 1 to 3.3 per 100 PY in era 2 and 3.2 per 100 PY in era 3. When these rates are formally compared with rate ratios, there was a 11% increase (IRR 1.11, 95% confidence interval [CI] 1.02-1.21) from era 1 to era 2, followed by an insignificant decrease (IRR 0.98, 95% CI 0.84-1.15) from era 2 to era 3, summating to an insignificant increase between era 1 and era 3 (IRR 1.09, 95% CI 0.95-1.25).
As shown in Fig. 2 , however, there was marked variability in the pattern of HCC incidence when stratified by diagnostic category. HCC incidence was highest for HBV and HCV patients, particularly in era 2 and era 3. Among HCV patients, HCC incidence increased from 4.5 per 100 PY in era 1, to 5.3 per 100 PY in era 2, and to 6.6 per 100 PY in era 3. The IRRs indicate significant increases for both transitions, with IRR of 1.19 (95% CI 1.06-1.33) between eras 1 and 2, and 1.26 (95% CI 1.03-1.54) between eras 2 and 3. For HBV patients, the rise in incidence was limited to the transition between eras 1 and 2 (IRR 1.93, 95% CI 1.27-2.92), which disappeared when eras 2 and 3 were compared (IRR 0.80, 95% CI 0.35-1.82). For other nonviral diagnoses, HCC incidence was lower than HBV or HCV, without an apparent trend over time (all P > 0.05 in pairwise comparisons of the eras). increased for all diagnoses over time; however, it was generally lower for HBV and HCV as well as alcoholic liver disease (Fig. 3A) . In fact, HCV was associated with the smallest increase in the transplant rate between eras 2 and 3 (IRR 1.35, compared with IRR 1.47 for all diagnoses combined) (Supporting Table  S1 ). Figure 3B shows a trend toward reduced waitlist deregistration for death or being too sick among HCV patients in the DAA era compared with the PI era, although this did not meet statistical significance (IRR 0.91, 95% CI 0.80-1.04) (Supporting Table  S2 ). Conversely, HCV patients experienced higher incidence of deregistration for improved condition in the DAA era (Fig. 3C) , with IRR 1.23 (95% CI 0.98-1.54) compared with the PI era and IRR 2.24 (95% CI 1.82-2.75) compared with the IFN era (Supporting Table S3 ). In light of these results, we performed univariate and multivariable Cox regression analyses in patients with HCV and HBV to take into account confounding variables that may potentially explain the rising trends in HCC incidence. In univariate analyses, the eras, age, race, sex, and Child-Turcotte-Pugh (CTP) score at baseline were significantly associated with increased hazard of developing HCC while on the wait list, whereas diabetes was not (Table 3 ). In the multivariable Cox proportional hazards analysis, the hazard ratio for development of de novo HCC in HCV patients in the DAA era, in comparison to the IFN era, was 1.22 (95% CI 1.01-1.48). There was an insignificant 6% increase in the risk of de novo HCC (hazard ratio [HR] 1.06, 95% CI 0.94-1.18) between the IFN and PI eras. For the 1178 patients listed with HBV, the wait-list registration era was not significantly associated with the hazards of HCC (Supporting Table S4 ). In both HBV and HCV patients, the age, higher Child-Pugh score, and nonwhite race were associated with incidence of HCC. In addition to the confounding factors, competing events that occur while waiting for LT may also affect the observed incidence of HCC. Table 4 summarizes the competing risk regression analysis in the 20,039 patients with HCV, with LT and death considered as competing risks. When adjusted for the same variables as in the Cox regression models, there was no association between era of wait listing and the development of de novo HCC, with sHR of 0.89 (95% CI 0.79-0.99) for era 2 and sHR of 0.83 (95% CI 0.69-1.00) for era 3, when compared with era 1. However, the male sex, older age, and nonwhite race remained predictive for incidence of HCC.
Discussion
In this work of incorporating a large, population-based observational cohort, we found an increased incidence of de novo HCC among wait-list registrants with end-stage liver disease and HCV in the DAA era. However, when other factors, including biological risk factors for HCC and transplant-related competing risks, are taken into account, patients in the DAA Table 3 ). Eventually, the era effect disappeared altogether in the multivariable competing risk analysis (sHR 0.83, 95% CI 0.69-1.00, Table 4 ). Following earlier reports that DAA-treated HCV patients who achieve SVR after initial therapy for HCC experience more frequent and aggressive recurrence, the effect of SVR on the risk of de novo and recurrent HCC in the DAA era has been fiercely debated. (30) Proponents of the association theorize that elimination of viral antigens may result in disruption in immune regulation, eventually resulting in a change in the tumor behavior. It is postulated that SVR induced by IFN could have less of an effect on HCC growth because of the immune-modulating effects of IFN.
Historical data from the IFN era estimate the incidence of HCC at approximately 1% after viral eradication, with an estimated risk reduction of 76% in SVR patients compared with non-SVR control patients with cirrhosis. (31, 32) In contrast, studies in the DAA era report a 3% to 7% annual incidence of de novo HCC after successful DAA therapy, (14, 17, 33) which is similar to untreated controls or nonresponders to DAA. Indeed, a recent meta-analysis of 26 studies reported an increased risk of de novo HCC in the DAA era, with a relative risk (RR) of 2.77 (95% CI 1.46-5.25) compared with the IFN era. (21) However, this difference disappeared after adjustment for age and follow-up time (RR 0.68, 95% CI 0.18-2.55). A similar effect was seen in an analysis of the Scottish HCV clinical database, with attenuation of the HR for de novo HCC from 2.48 to 1.15 after adjustment for several relevant covariates, including age, sex, and Child-Pugh score. (34) Our data show a similar pattern, in that covariates included in the multivariable Cox model explain in part the rise in HCC incidence in the DAA era. As the HCV-infected birth cohort ages, wait-list patients are older and present with more advanced liver disease, driving the risk of HCC higher.
The results of our competing risk analysis lend further insight about the higher observed incidence of HCC in the DAA era. Recent HCV patients were less frequently removed from the wait-list due to death or being too sick to undergo transplant and were more likely to be withdrawn from the list for an improved condition (Fig. 3) . The frequency of waitlist removal was much lower for improvement than for death or being too sick. Finally, although the rate of transplantation increased for all diagnoses, HCV patients experienced the lowest increase in the transplant rate. When taken together, these point to a scenario in which many HCV patients in the DAA era achieved SVR, and their condition did not deteriorate as much compared with HCV patients in previous eras, when only IFN-based therapies were available. During this period, a greater proportion of HCV patients remained on the wait-list, exposing them to longer periods of at-risk time to develop HCC.
Whether and how rapidly the risk of de novo HCC is altered by SVR in patients with established cirrhosis remains to be determined. It stands to reason that elimination of viral replication, hepatic inflammation, and fibrogenesis following SVR should diminish the carcinogenic risk in HCV cirrhosis. Recent analyses from the Veterans Affairs national healthcare system have demonstrated a reduction in the risk of incident HCC among DAA-treated cirrhotic patients. (22, 23) Accordingly, as more patients with HCV cirrhosis are treated with antiviral therapy or undergo LT, rates of incident HCC on the wait-list may in fact decrease.
Based on these findings, we believe that our results help to reconcile the conflicting data about the incidence and risk of HCC in the DAA era. These data corroborate a rising incidence of HCC among recent HCV patients; however, they also indicate that the observation is confounded by changes in the demographic and clinical profile of HCV patients, as well as changes in the course of their disease progression. These insights could not have been obtained from prior studies, as they tended to be limited by small sample size, potential selection bias, and short follow-up times. In addition, there is significant variation with regard to regional practices and baseline clinical characteristics. With 20,039 patients with decompensated HCV cirrhosis in our overall cohort, 6769 (33.8%) of whom entered the wait list in the DAA era, our investigation is one of the largest observational studies to date regarding the effect of DAA on incident HCC, particularly within the transplant population.
Our findings reiterate the importance of HCC in the natural history of patients with end-stage liver disease due to HCV. We observed high incidence rates of HCC (4.5-6.6 per 100 PY) in our cohort, even after excluding potentially prevalent cases by omitting patients who applied for HCC exception points within 180 days of listing. Previous analyses have estimated incidence rates of HCC among DAA-treated patients with advanced liver disease due to HCV to be approximately 1.8 to 3.6 per 100 PY in the DAA era. (21) (22) (23) 35) The high incidence of HCC observed in our study may reflect the severity of cirrhosis and decompensated liver disease and thus high risk of HCC in our U.S. wait-list population, as well as the fact that DAA therapy is not consistently prescribed to all LT candidates. In addition, compared with nontransplant candidates, patients on the LT wait list may be more closely monitored for the development of HCC. (36, 37) Consistent with prior evidence, older age, male sex, and nonwhite race remained independent risk factors for de novo HCC in our multivariable competing risk model. (29) Diabetes was not predictive in this cohort, adding to more recent evidence that patients with HCV cirrhosis and diabetes may not be at added risk for de novo HCC, compared with those without diabetes. (38) Together, these data strongly advocate for close surveillance for HCC in patients with advanced liver disease, and particularly those remaining on the LT wait list. Although the risk of HCC in individual patients may be reduced with DAA therapy, the absolute number of patients developing HCC may increase, particularly when there are a larger number of patients under observation, and for longer periods of time.
Our study also allows a comparison of the evolving incidence of HCC in patients with HCV versus other etiologies. An increased incidence of HCC was observed only among patients with HCV in era 3 compared with era 2 and era 1. Among HBV patients, an increase in incident HCC was seen in era 2 compared with era 1, but not in era 3, which could be related to the now widespread availability of HBV therapy and effective long-term viral suppression. However, the total number of HBV patients without pre-existing HCC exceptions on the LT wait list was small, so the CIs for these estimates are wide. There was no significant association between era of wait listing and de novo HCC in patients with nonalcoholic steatohepatitis or alcohol-related cirrhosis.
We do acknowledge several limitations of our study, which stem from its ecological nature in linking DAA availability with HCC and other wait-list outcomes. Patients' viremia status and pharmaceutical usage were not reported in the SRTR data, which prevent us from being able to distinguish whether the patient received DAA therapy and did in fact achieve SVR. In the most recent era, up to 95% of patients with HCV cirrhosis, even with hepatic decompensation, can achieve SVR with DAA therapy, making these patients no longer considered "difficult-to-treat." (39) Clearly, not all waitlist registrants are treated for their HCV, as some are too sick to receive therapy, whereas for others, DAAs may be withheld for fear of "MELD purgatory," a scenario in which successful treatment of HCV infection may attenuate disease progression and prevent the MELD score from escalating to the level needed to receive organ offers, without substantial improvement in symptoms or quality of life. An SRTR linkage with the Symphony database, an integrated data source of prescription and pharmacy coverage, showed that 211 (19%) of 1150 new wait-list registrants with HCV in 2014 received sofosbuvir. (40) The proportion of LT candidates receiving antiviral therapy while on the wait list is now likely higher, considering the wider availability and safety of DAA-based regimens approved for use in patients with decompensated disease. When only IFN-based regimens were available, decompensated cirrhosis was a relative contraindication to treatment. In our study, 87% of those listed with HCV prior to 2014 had either CTP B or C disease; therefore, the proportion of wait-list registrants who would have received HCV treatment in the pre-DAA eras were likely much lower than the observed 19% in 2014. Ultimately, we submit that the lack of treatment details in our data would tend to dilute the observation being made, and that had these specific data been available, the contrast between unadjusted and multivariable analyses may have been even more dramatic.
Our definition of de novo HCC was based on MELD exceptions and may not have captured patients who did not qualify or apply for exception, such as if they exceeded transplantable criteria or if their natural MELD obviated the need for exception. In addition, changes to the HCC exception policy occurred during the study time period, which lowered the initial exception points granted for HCC. (41) Although these factors could have led us to underestimate the true incidence of de novo HCC, it appears unlikely that they occurred frequently overall or differentially across the eras to have affected the trends seen in this analysis. Finally, the "HCC delay" policy, which implements a 6-month waiting period before granting HCC exception points, took effect in October 2015 and would not have tangibly affected our cohort, as we excluded patients applying for HCC exception within 180 days of listing, and recruitment for our study ended on December 31, 2015.
In summary, the incidence and risk of HCC among patients with advanced HCV cirrhosis registered for LT in the most recent era remain high. Although mechanistic studies could eventually reveal a link between DAA therapy and the evolution of HCC in HCV patients with cirrhosis, our Cox regression and competing risks analyses indicate that the observed increase in incident HCC on the U.S. transplant wait list may be attributable to the shift in the characteristics of HCV patients over time and changes in wait-list dynamics. As safer and more effective HCV therapies become available for patients with decompensated cirrhosis, more HCV patients on the LT wait list will have achieved SVR. Although new registrations and transplants for HCV in the United States are declining, there will remain a population of wait-list registrants with HCV who nonetheless require LT despite having achieved SVR, for complications of liver disease including HCC. (8, 42) Although more data are being generated to guide DAA treatment in patients with decompensated HCV cirrhosis, the need for close surveillance for HCC in patients with advanced liver disease, and particularly those remaining on the LT wait list, may not be overemphasized. (43) (44) (45) 
